{
    "symbol": "QTRX",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-08 22:38:24",
    "content": " Second quarter 2022 service revenue increased 51% versus the prior year second quarter to $8.5 million, included within services revenue is $2.7 million recognized during the second quarter of 2022 from our collaboration with Eli Lilly announced during our Q4 2021 release. Our pro-forma operating expenses totaled $31.6 million in the second quarter of 2022, an increase of $5.9 million versus operating expenses in the second quarter of 2021. Do we -- first of all, I think with me coming on board, I think it's natural that there is a strategic review of the operating model and then anyone new coming to our business is going to take a look up how we want to allocate our resources and our capital. Number two, we think this is an incredible time where there's several trials, several work and around research and diagnostics that's being done and a few therapeutics in the market that are becoming in the next couple of years. When we did the deep-dive, one of the things it highlighted is this cost of quality that Masoud talks to and the ongoing need to put additional resources and have additional expenses associated with product we work and getting it in a place where we can go to market, it's going to be a drag on us getting to cash flow breakeven."
}